LB Pharmaceuticals Inc (NASDAQ:LBRX) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$150M · US$34.94 a share · Leerink Partners +1 Dealers: Leerink Partners, Piper Sandler Buyers: Adage Capital Partners, L.P.; BB Biotech; Caligan Partners; Commodore Capital; Deep Track Capital; Farallon Capital Management; Integral Health Asset Management; Janus Henderson Investors; Spruce Street Capital; StemPoint Capital LP Use of proceeds: Expand LB-102 into new indications such as negative symptoms of schizophrenia and Alzheimer's agitation/psychosis, plus working capital and general purposes | Jul 29, 2026 |
| Private placement of common stock and pre-funded warrants Announced: about US$100M · US$21.17 a share · Leerink Partners +2 Dealers: Leerink Partners, Piper Sandler, Stifel Buyers: Balyasny Asset Management L.P.; Caligan Partners; Commodore Capital; Deep Track Capital; Nantahala Capital; Pivotal bioVenture Partners; Spruce Street Capital; TCGX; Trails Edge Capital Partners Use of proceeds: Fund a Phase 2 trial of LB-102 as adjunctive treatment for major depressive disorder, plus working capital and general corporate purposes | Feb 5, 2026 |
| Public offering of common stock Announced: US$285M · US$15 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Stifel (co-lead) | Sep 11, 2025 |